P-selectin Inhibitor for the Treatment of Sickle Cell Disease
Application
A glycopeptide inhibitor of p-selectin for the treatment of sickle cell disease.
Key Benefits
- Blocks the activity of P-selectin with nM affinity.
- Potential treatment for vaso-occlusive crisis associated with sickle cell disease.
- Inhibits the earliest stage of leukocyte activation helping to prevent immune response.
Market Summary
Sickle cell anemia, a serious disorder in which the body makes sickle-shaped red blood cells, affects thousands of Americans and a majority of these are African Americans. The most common clinical manifestation of sickle cell disease is vaso-occlusive crisis, which results in an average of 2.5 hospital visits per year for sickle cell patients in the U.S. Current treatments for vaso-occlusive crisis, such as opioids and rehydration, are primarily focused only the management of symptoms.
Technical Summary
P-selectin is a constitutively expressed carbohydrate-binding protein that helps activate leukocytes to initiate the inflammatory response in mammals. The best characterized ligand for P-selectin is called P-selectin glycoprotein ligand-1 (PSGL-1) which is expressed on the surface membranes of all leukocytes. PSGL-1 supports leukocyte recruitment in both innate and adaptive arms of the immune response. Because PSGL-1 plays an important role in vascular endothelial signaling, a PSGL-1 mimetic with the ability to block the activity of P-selectin has the potential to treat multiple indications, such as sickle cell anemia vaso-occlusive crisis, vascular inflammation, and thrombosis.
Developmental Stage
In vivo studies in mice show efficient blockade of P-selectin-dependent binding of leukocytes to the activated endothelium of blood vessels.
Patent Information
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Patent Status |
| EP Registered Country |
France |
14806846.3 |
3004139 |
5/23/2014 |
5/6/2020 |
Issued |
| EP Registered Country |
Germany |
14806846.3 |
3004139 |
5/23/2014 |
5/6/2020 |
Issued |
| EP Registered Country |
Netherlands |
14806846.3 |
3004139 |
5/23/2014 |
5/6/2020 |
Issued |
| EP Registered Country |
United Kingdom |
14806846.3 |
3004139 |
5/23/2014 |
5/6/2020 |
Issued |
| EP Registered Country |
Switzerland |
14806846.3 |
3004139 |
5/23/2014 |
5/6/2020 |
Issued |
| Nationalized PCT - Foreign |
Canada |
2,914,470 |
2,914,470 |
12/2/2015 |
9/27/2022 |
Issued |
| Nationalized PCT - United States |
United States |
14/895,606 |
10,253,071 |
12/3/2015 |
4/9/2019 |
Issued |
| Nationalized PCT - Foreign |
EP |
14806846.3 |
3004139 |
12/11/2015 |
5/6/2020 |
Issued |
| Divisional |
United States |
16/352,585 |
12,162,960 |
3/13/2019 |
12/10/2024 |
Issued |
|
|
